Cord Blood America Inc. announced earnings results for the fourth quarter and full year ended December 31, 2016. Total revenue for the fourth quarter 2016 was $0.73 million, a decrease of 33.9% from total revenue of $1.11 million for the fourth quarter 2015. EBITDA for the fourth quarter 2016 was negative $0.10 million compared to EBITDA of $0.10 million for the fourth quarter 2015. Of the $0.38 million decrease, $0.27 million was attributable to the ceasing of orders in March 2016 within the tissue procurement business and $0.03 million was attributable to the reduction in storage and processing revenue from a previously terminated agreement with a third party. Net income for the three-month period ended December 31, 2016 was $0.002 million compared to net income of $0.02 million for the period ended December 31, 2015. Excluding the $0.23 million of total severance expense and $0.01 million of expense associated with the strategic review process incurred in the quarter, EBITDA would have been $0.14 million, a $0.04 million increase compared to $0.10 million in fourth quarter 2015 despite the reduction in revenue as the company continues to reduce costs to offset the loss in revenue. Total revenue for the year ended December 31, 2016 was $3.29 million, a decrease of 37.1% from total revenue of $5.23 million for the year ended December 31, 2015. EBITDA for the year ended December 31, 2016 was $0.27 million compared to EBITDA of $0.76 million for the year ended December 31, 2015. Of the $1.94 million decrease in revenue, $1.56 million was attributable to the ceasing of tissue procurement orders and $0.22 million was attributable to the reduction in storage and processing revenue from the third party. Net income for fiscal year 2016 was $0.10 million compared to net income of $0.44 million for fiscal 2015. Excluding the $0.32 million of total severance expense and $0.04 million of expense associated with the strategic review process incurred during the fiscal year, EBITDA would have been $0.62 million compared to $0.76 million in fiscal 2015. Excluding the $0.32 million of total severance expense and $0.04 million of expense associated with the strategic review process incurred during the fiscal year, EBITDA would have been $0.62 million compared to $0.76 million in fiscal 2015.